How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2026 · second_quarter · Q2
Rare kidney disease
Rare kidney disease
Rare kidney disease
Source: Senate LDA
Rare kidney disease
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2026 · first_quarter · Q1
Rare kidney disease
Rare kidney disease
Rare kidney disease
Rare kidney disease
Filing targets: HOUSE OF REPRESENTATIVES
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2025 · fourth_quarter · Q4
Rare kidney disease
Rare kidney disease
Rare kidney disease
Rare kidney disease
Filing targets: HOUSE OF REPRESENTATIVES
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2025 · third_quarter · Q3
Rare kidney disease
Rare kidney disease
Rare kidney disease
Rare kidney disease
Filing targets: HOUSE OF REPRESENTATIVES
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2025 · second_quarter · Q2
Rare kidney disease
Rare kidney disease
Rare kidney disease
Rare kidney disease
Filing targets: HOUSE OF REPRESENTATIVES
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2025 · first_quarter · Q1
Rare kidney disease
Rare kidney disease
Rare kidney disease
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2024 · fourth_quarter · Q4
Rare kidney disease
Rare kidney disease
rare kidney disease
Rare kidney disease
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2024 · third_quarter · Q3
Rare kidney disease
rare kidney disease
Rare kidney disease
Rare kidney disease
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2024 · second_quarter · Q2
rare kidney disease
Rare kidney disease
Rare kidney disease
Rare kidney disease
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2024 · first_quarter · Q1
Rare kidney disease
Rare kidney disease
Rare kidney disease
rare kidney disease
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2023 · fourth_quarter · Q4
Rare kidney disease
Rare kidney disease
Rare kidney disease
rare kidney disease
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2023 · third_quarter · Q3
Rare kidney disease
Rare kidney disease
rare kidney disease
Rare kidney disease
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2023 · second_quarter · 2A
Rare kidney disease
Rare kidney disease
Rare kidney disease
rare kidney disease
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2023 · second_quarter · Q2
Rare kidney disease
Rare kidney disease
Rare kidney disease
rare kidney disease
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2023 · first_quarter · Q1
rare kidney disease
Rare kidney disease
Rare kidney disease
Rare kidney disease
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2022 · fourth_quarter · Q4
Rare kidney disease
Rare kidney disease and health equity
Rare kidney disease
Rare kidney disease
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2022 · third_quarter · Q3
Rare kidney disease
Rare kidney disease
Rare kidney disease
Rare kidney disease and health equity
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2022 · second_quarter · Q2
Rare kidney disease
Rare kidney disease
Rare kidney disease
Rare kidney disease
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2022 · first_quarter · Q1
Rare kidney disease
Rare kidney disease
Rare kidney disease
Rare kidney disease
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2021 · fourth_quarter · Q4
Rare kidney disease
Rare kidney disease
Rare kidney disease
Rare kidney disease
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2021 · third_quarter · 3A
Rare kidney disease
Rare kidney disease
Rare kidney disease
Rare kidney disease
TRAVERE THERAPEUTICS via THE HEALTH EQUITY STRATEGIES GROUP, LLC
2021 · third_quarter · RR
Educating congressional offices -- with a focus on minority caucus offices -- about rare kidney disease and a forthcoming legislative measure to address this issue.
Educating congressional offices -- with a focus on minority caucus offices -- about rare kidney disease and a forthcoming legislative measure to address this issue.
Educating congressional offices -- with a focus on minority caucus offices -- about rare kidney disease and a forthcoming legislative measure to address this issue.
Rare kidney disease
Filing targets: HOUSE OF REPRESENTATIVES
Filing targets: HOUSE OF REPRESENTATIVES
Filing targets: HOUSE OF REPRESENTATIVES
Filing targets: HOUSE OF REPRESENTATIVES
Filing targets: HOUSE OF REPRESENTATIVES
Filing targets: HOUSE OF REPRESENTATIVES
Filing targets: HOUSE OF REPRESENTATIVES
Filing targets: HOUSE OF REPRESENTATIVES
Educating congressional offices -- with a focus on minority caucus offices -- about rare kidney disease and a forthcoming legislative measure to address this issue.